No Data
No Data
Press Release: AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
AngioDynamics, Inc. (NASDAQ:ANGO) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
AngioDynamics Analyst Ratings
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $14
Institutional Investors Have a Lot Riding on AngioDynamics, Inc. (NASDAQ:ANGO) With 74% Ownership